PROMISING CANCER DRUGS WON'T GO FAR UNLESS EVERYONE GETS GENETIC TESTING

MIT Technology Review  June 6, 2017

Dan Rhodes, Strata's co-founder and CEO, comments on the need to provide cancer patients broad access to tumor profiling to identify those who will benefit from targeted therapy drugs. Read the article here.

IN LANDMARK MOVE, FDA APPROVES CANCER DRUG FOR A BIOMARKER NOT A TISSUE

MedCity News  May 24, 2017

Dr. Scott Tomlins, Strata's co-founder and Laboratory Director, comments on the accelerated approval of Keytruda for MSI-H and dMMR cancers and the opportunity to accelerate the approval of additional precision therapies in biomarker-defined patient populations. At Strata Oncology, we believe that by institutionalizing tumor sequencing and clinical trial participation across a large network of hospitals, we can help usher in the next wave of biomarker-guided precision medicine approvals. Read the article here.

 

STRATA ONCOLOGY, INC. ANNOUNCES LAUNCH OF STRATA NGS TEST

Ann Arbor, MI, May 23, 2017

UAB CANCER CENTER PROVIDES NO-COST TUMOR PROFILING FOR PATIENTS WITH ADVANCED OR RARE CANCERS

Birmingham, AL, May 19, 2017

Strata oncology announces collaboration with epizyme to support tazmetostat clinical development

Ann Arbor, MI, February 6, 2017

CLOVIS ONCOLOGY AND STRATA ONCOLOGY ANNOUNCE COLLABORATION TO ACCELERATE ENROLLMENT IN RUCAPARIB PROSTATE CANCER DEVELOPMENT PROGRAM

Boulder, CO & Ann Arbor, MI, February 1, 2017

STRATA ONCOLOGY LAUNCHES THE STRATA TRIAL WITH FIRST CANCER CENTER PARTNERS

Ann Arbor, MI, December 16, 2016

STRATA ONCOLOGY COMPLETES SERIES A FINANCING AND SIGNS STRATEGIC PARTNERSHIP WITH THERMO FISHER SCIENTIFIC

Ann Arbor, MI, June 1, 2016

 

Contact:

media@strataoncology.com

734-527-1000

.